A 12 month survey of candidaemia in Scotland, UK, in which every Scottish hospital laboratory submitted all blood isolates of yeasts for identification, strain typing and susceptibility testing, provided 300 isolates from 242 patients, generating incidence data of 4.8 cases per 100 000 population per year and 5.9 cases per 100 000 acute occupied bed days; 27.9 % of cases occurred in intensive care units. More than half the patients with candidaemia had an underlying disease involving the abdomen, 78 % had an indwelling intravenous catheter, 62 % had suffered a bacterial infection within the 2 weeks prior to candidaemia and 37 % had undergone a laparotomy. Candida albicans was the infecting species in 50 % of cases, followed by Candida glabrata (21 %) and Candida parapsilosis (12 %). Seven cases of candidaemia were caused by Candida dubliniensis, which was more prevalent even than Candida lusitaniae and Candida tropicalis (six cases each). Among C. glabrata isolates, 55 % showed reduced susceptibility to fluconazole, but azole resistance among other species was extremely low. Multilocus sequence typing showed isolates with high similarity came from different hospitals across the country, and many different types came from the hospitals that submitted the most isolates, indicating no tendency towards hospital-specific endemic strains. Multiple isolates of C. albicans and C. glabrata from individual patients were of the same strain type with single exceptions for each species. The high prevalence of candidaemia in Scotland, relative to other population-based European studies, and the high level of reduced fluconazole susceptibility of Scottish C. glabrata isolates warrant continued future surveillance of invasive Candida infections.
AlmiranteB.,
RodriguezD.,
ParkB. J.,
Cuenca-EstrellaM.,
PlanesA. M.,
AlmelaM.,
MensaJ.,
SanchezF.,
AyatsJ.other authors2005; Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance. Barcelona, Spain: from 2002 to 2003J Clin Microbiol 43:1829–1835[CrossRef]
AndesD.2004; Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Updat 7:185–194[CrossRef]
AndesD.,
van OgtropH.1999; Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43:2116–2120
ArendrupM. C.,
FuurstedK.,
Gahrn-HansenB.,
JensenI. M.,
KnudsenJ. D.,
LundgrenB.,
SchonheyderH. C.,
TvedeM.2005; Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43:4434–4440[CrossRef]
Arthington-SkaggsB. A.,
Lee-YangW.,
CiblakM. A.,
FradeJ. P.,
BrandtM. E.,
HajjehR. A.,
HarrisonL. H.,
SofairA. N.,
WarnockD. W.2002; Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 46:2477–2481[CrossRef]
AsmundsdottirL. R.,
ErlendsdottirH.,
GottfredssonM.2002; Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40:3489–3492[CrossRef]
BlignautE.,
PujolC.,
LockhartS.,
JolyS.,
SollD. R.2002; Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J Clin Microbiol 40:826–836[CrossRef]
BlijlevensN. M. A.,
DonnellyJ. P.,
de PauwB. E.2002; Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117:259–264[CrossRef]
BlumbergH. M.,
JarvisW. R.,
SoucieJ. M.,
EdwardsJ. E.,
PattersonJ. E.,
PfallerM. A.,
Rangel-FraustoM. S.,
RinaldiM. G.,
SaimanL.other authors2001; Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177–186[CrossRef]
BougnouxM. E.,
TavantiA.,
BouchierC.,
GowN. A. R.,
MagnierA.,
DavidsonA. D.,
MaidenM. C. J.,
d'EnfertC.,
OddsF. C.2003; Collaborative consensus for optimized multilocus sequence typing of Candida albicans
. J Clin Microbiol 41:5265–5266[CrossRef]
CohenR.,
RothF. J.,
DelgadoE.,
AhearnD. G.,
KalserM. H.1969; Fungal flora of the normal human small and large intestine. N Engl J Med 280:638–641[CrossRef]
Cuenca-EstrellaM.,
Lee-YangW.,
CiblakM. A.,
Arthington-SkaggsB. A.,
MelladoE.,
WarnockD. W.,
Rodriguez-TudelaJ. L.2002b; Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 46:3644–3647[CrossRef]
Cuenca-EstrellaM.,
MooreC. B.,
BarchiesiF.,
BilleJ.,
ChryssanthouE.,
DenningD. W.,
DonnellyJ. P.,
DromerF.,
DupontB.other authors2003; Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST. Clin Microbiol Infect 9:467–474[CrossRef]
Cuenca-EstrellaM.,
Gomez-LopezA.,
MelladoE.,
Rodriguez-TudelaJ. L.2005; Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 11:486–492[CrossRef]
DiekemaD. J.,
MesserS. A.,
BrueggemannA. B.,
CoffmanS. L.,
DoernG. V.,
HerwaldtL. A.,
PfallerM. A.2002; Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298–1302[CrossRef]
FeilE. J.,
LiB. C.,
AanensenD. M.,
HanageW. P.,
SprattB. G.2004; eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186:1518–1530[CrossRef]
HajjehR. A.,
SofairA. N.,
HarrisonL. H.,
LyonG. M.,
Arthington-SkaggsB. A.,
MirzaS. A.,
PhelanM.,
MorganJ.,
Lee-YangW.other authors2004; Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42:1519–1527[CrossRef]
KaoA. S.,
BrandtM. E.,
PruittW. R.,
ConnL. A.,
PerkinsB. A.,
StephensD. S.,
BaughmanW. S.,
ReingoldA. L.,
RothrockG. A.other authors1999; The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29:1164–1170[CrossRef]
KibblerC. C.,
SeatonS.,
BarnesR. A.,
GransdenW. R.,
HollimanR. E.,
JohnsonE. M.,
PerryJ. D.,
SullivanD. J.,
WilsonJ. A.2003; Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54:18–24[CrossRef]
LevyI.,
RubinL. G.,
VasishthaS.,
TucciV.,
SoodS. K.1998; Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26:1086–1088[CrossRef]
MarcoF.,
DanesC.,
AlmelaM.,
JuradoA.,
MensaJ.,
de la BellacasaJ. P.,
EspasaM.,
MartinezJ. A.,
de AntaM. T. J.2003; Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996–2001. Diagn Microbiol Infect Dis 46:259–264[CrossRef]
McNeilM. M.,
NashS. L.,
HajjehR. A.,
PhelanM. A.,
ConnL. A.,
PlikaytisB. D.,
WarnockD. W.2001; Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33:641–647[CrossRef]
MeisJ. F. G. M.,
RuhnkeM.,
de PauwB. E.,
OddsF. C.,
SiegertW.,
VerweijP. E.1999; Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5:150–153[CrossRef]
OddsF. C.,
BernaertsR.1994; CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 32:1923–1929
OddsF. C.,
VranckxL.,
WoestenborghsF.1995; Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 39:2051–2060[CrossRef]
PemánJ.,
CantonE.,
GobernadoM.2005; Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24:23–30[CrossRef]
PfallerM. A.,
DiekemaD. J.,
JonesR. N.,
MesserS. A.,
HollisR. J.2002; Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program; 1997 to 2000J Clin Microbiol 40:852–856[CrossRef]
PfallerM. A.,
DiekemaD. J.,
SheehanD. J.2006; Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19:435–447[CrossRef]
PriceM. F.,
LaroccoM. T.,
GentryL. O.1994; Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 38:1422–1424[CrossRef]
PujolC.,
PfallerM.,
SollD. R.2002; Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J Clin Microbiol 40:2729–2740[CrossRef]
Rangel-FraustoM. S.,
WiblinT.,
BlumbergH. M.,
SaimanL.,
PattersonJ.,
RinaldiM.,
PfallerM.,
EdwardsJ. E.,
JarvisW.other authors1999; National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29:253–258[CrossRef]
RexJ. H.,
NelsonP. W.,
PaetznickV. L.,
LozanochiuM.,
EspinelingroffA.,
AnaissieE. J.1998; Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42:129–134
San MiguelL. G.,
CoboJ.,
OtheoE.,
Sanchez-SousaA.,
AbrairaV.,
MorenoS.2005; Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis
. Infect Control Hosp Epidemiol 26:548–552[CrossRef]
StoneH. H.,
KoldL. D.,
CurrieC. A.,
GeheberC. E.,
CuzzellJ. Z.1974; Candida sepsis: pathogenesis and principles of treatment. Ann Surg 179:697–711[CrossRef]
TavantiA.,
DavidsonA. D.,
GowN. A. R.,
MaidenM. C. J.,
OddsF. C.2005a; Candida orthopsilosis and Candida metapsilosis spp. nov to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292[CrossRef]
TavantiA.,
DavidsonA. D.,
FordyceM. J.,
GowN. A. R.,
MaidenM. C. J.,
OddsF. C.2005b; Population structure and properties of Candida albicans , as determined by multilocus sequence typing. J Clin Microbiol 43:5601–5613[CrossRef]
TavantiA.,
DavidsonA. D.,
JohnsonE. M.,
MaidenM. C. J.,
ShawD. J.,
GowN. A. R.,
OddsF. C.2005c; Multilocus sequence typing for differentiation of strains of Candida tropicalis
. J Clin Microbiol 43:5593–5600[CrossRef]
TrickW. E.,
FridkinS. K.,
EdwardsJ. R.,
HajjehR. A.,
GaynesR. P.2002; Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630[CrossRef]
VazquezJ. A.,
SobelJ. D.2003; Candidiasis. In Clinical Mycology pp 143–187 Edited by
DismukesW. E.,
PappasP. G,
SobelJ. D.
Oxford: Oxford University Press;